- Kymera Therapeutics Chief Operating Officer Jeremy G. Chadwick cut direct holdings to 61,202 shares.
- Chadwick sold 22,240 shares on March 31 and April 1 at prices around $85.38 to $86.05.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-138371), on April 01, 2026, and is solely responsible for the information contained therein.
Comments